Personalised chemotherapy based on tumour marker decline in poor-prognosis germ-cell tumours: results of the GETUG 13 phase III trial

BACKGROUND: Poor-prognosis germ-cell tumours (GCT) are associated with only a 50% cure rate. Our hypothesis was that treatment intensification based on an early tumour marker decline will improve progression-free survival (PFS). METHODS: In this phase III, multicentre, international trial (NCT001046...

Full description

Saved in:
Bibliographic Details
Published in:Lancet Oncol
Main Authors: Fizazi, Karim, Pagliaro, Lance, Laplanche, Agnes, Fléchon, Aude, Mardiak, Josef, Geoffrois, Lionnel, Kerbrat, Pierre, Chevreau, Christine, Delva, Remy, Rolland, Frederic, Theodore, Christine, Roubaud, Guilhem, Gravis, Gwenaëlle, Eymard, Jean-Christophe, Malhaire, Jean-Pierre, Linassier, Claude, Habibian, Muriel, Martin, Anne-Laure, Journeau, Florence, Reckova, Maria, Logothetis, Christopher, Culine, Stephane
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4400870/
https://ncbi.nlm.nih.gov/pubmed/25456363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70490-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items